Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 5 Cardiotoxicity 2 Solid Tumors 1 Prostatic Neoplasms 1 Inflammation 1 Hyperglycemia 1 Hereditary Sensory and Autonomic Neuropathies 1 Heart Failure 1

Interventions

atezolizumab 3 Docetaxel 3 pembrolizumab 2 olaparib 2 lenvatinib 2 Leucovorin 2 Irinotecan 2 Immune Checkpoint Inhibitors 2 Fluorouracil 2 Filgrastim 2 Capecitabine 2 zolbetuximab 1 tomivosertib 1 spartalizumab 1 somatostatin receptor 2 1 pralsetinib 1 pegylated granulocyte colony-stimulating factor 1 necitumumab 1 motesanib diphosphate 1 ipatasertib 1 inavolisib 1 entrectinib 1 ensartinib 1 dapagliflozin 1 cobimetinib 1 cemiplimab 1 cat's claw extract 1 balugrastim 1 anlotinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Solid Tumors × dapagliflozin × Clear all

NCT07018622 2026-03-11

DAPA-ARMOR

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡